Literature DB >> 11535216

Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM).

S Garg1, R A Anderson, C J Chany, D P Waller, X H Diao, K Vermani, L J Zaneveld.   

Abstract

Vaginal prophylactic methodology may prevent heterosexual transmission of the HIV and other sexually transmitted disease-causing organisms as well as unplanned pregnancies. A new delivery system (ACIDFORM) was designed with acid-buffering, bioadhesive, and viscosity-retaining properties to (1) maintain the acidic vaginal milieu (the low pH inactivates many pathogens and spermatozoa), (2) form a protective layer over the vaginal/cervical epithelium (minimizing contact with pathogenic organisms), and (3) provide long-term vaginal retention. A Phase I clinical study with ACIDFORM provided initial information about its safety and showed the formation of a layer over the vaginal/cervical epithelium [1; Amaral et al., Contraception 1999;60:361-6]. To study the properties of the gel (without active ingredient) in more detail, ACIDFORM's acid-buffering, bioadhesive, viscosity-retaining, and spermicidal properties were compared in vitro to marketed formulations, and its long-term stability was assessed. ACIDFORM, either when titrated with NaOH or when mixed directly with semen, is highly acid buffering and much more effective than Aci-Jel, a commercial acid-buffering vaginal product. ACIDFORM adheres well to two model membranes (excised sheep vagina and cellophane) and is more bioadhesive than Conceptrol, Advantage S, Replens, Aci-Jel, and K-Y jelly. On dilution, ACIDFORM also retains its viscosity better than these marketed products. ACIDFORM is spermicidal and is stable for at least 2 years. These results suggest that ACIDFORM has advantages over presently marketed vaginal delivery systems. The gel may either be useful by itself as an antimicrobial contraceptive product or as a formulation vehicle for an active ingredient with antimicrobial and/or contraceptive properties.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535216     DOI: 10.1016/s0010-7824(01)00217-7

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  22 in total

1.  An Update on Vaginal Microbicides.

Authors:  Christine Mauck; Gustavo Doncel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

2.  A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis.

Authors:  Jose A Simoes; Luis G Bahamondes; Rodrigo P S Camargo; Valeria M N Alves; Lourens J D Zaneveld; Donald P Waller; Jill Schwartz; Marianne M Callahan; Christine K Mauck
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 3.  Vaginal drug delivery systems for HIV prevention.

Authors:  Lisa Cencia Rohan; Alexandra B Sassi
Journal:  AAPS J       Date:  2009-02-05       Impact factor: 4.009

Review 4.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 5.  Vaginal microbicides: a novel approach to preventing sexual transmission of HIV.

Authors:  Gustavo Doncel; Christine Mauck
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

6.  Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel.

Authors:  Satheesh Podaralla; Carsten Alt; Gita N Shankar
Journal:  AAPS PharmSciTech       Date:  2014-04-30       Impact factor: 3.246

7.  Effect of treatment assignment on intravaginal cleansing in a randomized study of the diaphragm with candidate microbicide.

Authors:  Ana Penman-Aguilar; Jennifer Legardy-Williams; Abigail Norris Turner; Tiana O O Rabozakandriana; D'Nyce Williams; Sandra Razafindravoavy; Frieda Behets; Kathleen Van Damme; Denise J Jamieson
Journal:  J Womens Health (Larchmt)       Date:  2011-02       Impact factor: 2.681

Review 8.  The importance of the vaginal delivery route for antiretrovirals in HIV prevention.

Authors:  Lindsay M Ferguson; Lisa Cencia Rohan
Journal:  Ther Deliv       Date:  2011-12

9.  Vaginal microbicide and diaphragm use for sexually transmitted infection prevention: a randomized acceptability and feasibility study among high-risk women in Madagascar.

Authors:  Frieda M Behets; Abigail Norris Turner; Kathleen Van Damme; Ny Lovaniaina Rabenja; Noro Ravelomanana; Teresa A Swezey; April J Bell; Daniel R Newman; D'Nyce L Williams; Denise J Jamieson
Journal:  Sex Transm Dis       Date:  2008-09       Impact factor: 2.830

10.  Chitosan gels for the vaginal delivery of lactic acid: relevance of formulation parameters to mucoadhesion and release mechanisms.

Authors:  Maria Cristina Bonferoni; Paolo Giunchedi; Santo Scalia; Silvia Rossi; Giuseppina Sandri; Carla Caramella
Journal:  AAPS PharmSciTech       Date:  2006       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.